Diacerein has a weak effect on the catabolic pathway of human osteoarthritis synovial fibroblast--comparison to its effects on osteoarthritic chondrocytes.

OBJECTIVES Synoviocytes play a crucial role in the inflammatory response leading to structural damage in OA. Our aim was to assess the effects of diacerein and NSAIDs on cellular responses of synoviocytes associated with inflammation and structural integrity of cartilage in OA. METHODS The effects of diacerein, celecoxib, diclofenac, meloxicam and indomethacin on prostaglandin (PG) E2 production, cyclo-oxygenase-2 (COX-2) protein expression, nitrite levels, presence of MMP-1 and -13, and activation of nuclear factor-kappaB (NF-kappaB) were studied on stimulated OA synoviocytes and chondrocytes. RESULTS Diacerein and NSAIDs inhibited IL-1beta-stimulated NF-kappaB activation in synoviocytes and chondrocytes except indomethacin in synoviocytes. Diacerein further increased COX-2 protein expression and PGE2 synthesis in synoviocytes stimulated with IL-1beta, while no effect was observed on stimulated chondrocytes. NSAIDs diminished until almost basal levels PGE2 release in both cells and, surprisingly, these drugs also diminished COX-2 protein expression both in synoviocytes and chondrocytes. With regard to structural mediators, diacerein decreased MMP-13 levels in synoviocytes but did not modify MMP-1 presence. NSAIDs induced a significant increase in MMP-1 levels in both cell types and in MMP-13 levels in chondrocytes. CONCLUSIONS Diacerein does not seem to reduce but rather increase inflammatory mediators in synoviocytes, while it does not overall affect chondrocyte inflammatory profile.

[1]  L. Slice,et al.  Ang II and EGF synergistically induce COX‐2 expression via CREB in intestinal epithelial cells , 2008, Journal of cellular physiology.

[2]  F. Legendre,et al.  Rhein, a diacerhein-derived metabolite, modulates the expression of matrix degrading enzymes and the cell proliferation of articular chondrocytes by inhibiting ERK and JNK-AP-1 dependent pathways. , 2007, Clinical and experimental rheumatology.

[3]  G. Herrero-Beaumont,et al.  Long term NSAID treatment inhibits COX-2 synthesis in the knee synovial membrane of patients with osteoarthritis: differential proinflammatory cytokine profile between celecoxib and aceclofenac , 2006, Annals of the rheumatic diseases.

[4]  G. Verbruggen.  Chondroprotective drugs in degenerative joint diseases. , 2006, Rheumatology.

[5]  S. Abramson,et al.  The fibroblast-like synovial cell in rheumatoid arthritis: a key player in inflammation and joint destruction. , 2005, Clinical immunology.

[6]  B. Bresnihan,et al.  Synovial tissue inflammation in early and late osteoarthritis , 2005, Annals of the rheumatic diseases.

[7]  A. Takeshita,et al.  Interleukin-1 stimulates cytokines, prostaglandin E2 and matrix metalloproteinase-1 production via activation of MAPK/AP-1 and NF-kappaB in human gingival fibroblasts. , 2005, Cytokine.

[8]  B. Aggarwal,et al.  Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-κB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation , 2004, Oncogene.

[9]  F. Berenbaum,et al.  The regulation of chondrocyte function by proinflammatory mediators: prostaglandins and nitric oxide. , 2004, Clinical orthopaedics and related research.

[10]  G. Herrero-Beaumont,et al.  EP2/EP4 signalling inhibits monocyte chemoattractant protein-1 production induced by interleukin 1β in synovial fibroblasts , 2004, Annals of the rheumatic diseases.

[11]  F. Berenbaum.  Signaling transduction: target in osteoarthritis , 2004, Current opinion in rheumatology.

[12]  M. Dougados,et al.  Evaluation of the symptomatic and structural efficacy of a new hyaluronic acid compound, NRD101, in comparison with diacerein and placebo in a 1 year randomised controlled study in symptomatic knee osteoarthritis , 2004, Annals of the rheumatic diseases.

[13]  Steven A Olson,et al.  The role of biomechanics and inflammation in cartilage injury and repair. , 2004, Clinical orthopaedics and related research.

[14]  Beth Apsel,et al.  Cyclooxygenase-2-Derived E Prostaglandins Down-Regulate Matrix Metalloproteinase-1 Expression in Fibroblast-Like Synoviocytes via Inhibition of Extracellular Signal-Regulated Kinase Activation 1 , 2003, The Journal of Immunology.

[15]  M. Beppu,et al.  Prostaglandin E2 is an enhancer of interleukin-1beta-induced expression of membrane-associated prostaglandin E synthase in rheumatoid synovial fibroblasts. , 2003, Arthritis and rheumatism.

[16]  J. Pujol,et al.  Rhein Inhibits Interleukin-1β-Induced Activation of MEK/ERK Pathway and DNA Binding of NF-κB and AP-1 in Chondrocytes Cultured in Hypoxia: A Potential Mechanism for Its Disease-Modifying Effect in Osteoarthritis , 2003, Inflammation.

[17]  J. Reginster,et al.  Effects of rhein on human articular chondrocytes in alginate beads. , 2003, Biochemical pharmacology.

[18]  Natsuki Segami,et al.  Relationships between pain-related mediators and both synovitis and joint pain in patients with internal derangements and osteoarthritis of the temporomandibular joint. , 2002, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[19]  T. Sasaguri,et al.  Transcriptional and Posttranscriptional Regulation of Cyclooxygenase-2 Expression by Fluid Shear Stress in Vascular Endothelial Cells , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[20]  T. Tanabe,et al.  Cyclooxygenase isozymes and their gene structures and expression. , 2002, Prostaglandins & other lipid mediators.

[21]  Tomomi Shirai,et al.  Pharmacological studies of diacerein in animal models of inflammation, arthritis and bone resorption. , 2002, European journal of pharmacology.

[22]  C. Gabay,et al.  Primary human articular chondrocytes, dedifferentiated chondrocytes, and synoviocytes exhibit differential responsiveness to interleukin‐4: Correlation with the expression pattern of the common receptor gamma chain , 2002, Journal of cellular physiology.

[23]  M. Currie,et al.  Cyclooxygenase 2-dependent prostaglandin E2 modulates cartilage proteoglycan degradation in human osteoarthritis explants. , 2002, Arthritis and rheumatism.

[24]  T. Yoshino,et al.  Prostaglandin E2 Inhibits IL-18-Induced ICAM-1 and B7.2 Expression Through EP2/EP4 Receptors in Human Peripheral Blood Mononuclear Cells1 , 2002, The Journal of Immunology.

[25]  J. Pelletier,et al.  Synthesis of interleukin 1beta, tumor necrosis factor-alpha, and interstitial collagenase (MMP-1) is eicosanoid dependent in human osteoarthritis synovial membrane explants: interactions with antiinflammatory cytokines. , 2002, The Journal of rheumatology.

[26]  C. Brinckerhoff,et al.  IL-1 induces collagenase-3 (MMP-13) promoter activity in stably transfected chondrocytic cells: requirement for Runx-2 and activation by p38 MAPK and JNK pathways. , 2001, Nucleic acids research.

[27]  M. Dougados,et al.  Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Evaluation of the Chondromodulating Effect of Diacerein in OA of the Hip. , 2001, Arthritis and rheumatism.

[28]  C. Brinckerhoff,et al.  Early response genes induced in chondrocytes stimulated with the inflammatory cytokine interleukin-1beta , 2001, Arthritis research.

[29]  A. Mancini,et al.  Prostaglandin E2 Regulates the Level and Stability of Cyclooxygenase-2 mRNA through Activation of p38 Mitogen-activated Protein Kinase in Interleukin-1β-treated Human Synovial Fibroblasts* , 2001, The Journal of Biological Chemistry.

[30]  T. Sato,et al.  Rhein, an active metabolite of diacerein, down-regulates the production of pro-matrix metalloproteinases-1, -3, -9 and -13 and up-regulates the production of tissue inhibitor of metalloproteinase-1 in cultured rabbit articular chondrocytes. , 2001, Osteoarthritis and cartilage.

[31]  Y. Konttinen,et al.  Fibroblast biology: Signals targeting the synovial fibroblast in arthritis , 2000, Arthritis Research.

[32]  K. Goa,et al.  Celecoxib , 2000, Drugs.

[33]  M. Yaron,et al.  Anti-interleukin-1 effects of diacerein and rhein in human osteoarthritic synovial tissue and cartilage cultures. , 1999, Osteoarthritis and cartilage.

[34]  P. Elliott,et al.  Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[35]  J. Pelletier,et al.  Diacerhein and rhein reduce the interleukin 1beta stimulated inducible nitric oxide synthesis level and activity while stimulating cyclooxygenase-2 synthesis in human osteoarthritic chondrocytes. , 1998, The Journal of rheumatology.

[36]  M. Tod,et al.  Clinical Pharmacokinetics of Diacerein , 1998, Clinical pharmacokinetics.

[37]  C. Rorabeck,et al.  Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. , 1997, The Journal of clinical investigation.

[38]  D. Türck,et al.  A review of the clinical pharmacokinetics of meloxicam. , 1996, British journal of rheumatology.

[39]  F. Berenbaum,et al.  Synergistic Effect of Interleukin-1β and Tumor Necrosis Factor α on PGE2Production by Articular Chondrocytes Does Not Involve PLA2Stimulation , 1996 .

[40]  J. Whitehead,et al.  Effects of antiinflammatory drugs on the progression of osteoarthritis of the knee. LINK Study Group. Longitudinal Investigation of Nonsteroidal Antiinflammatory Drugs in Knee Osteoarthritis. , 1995, The Journal of rheumatology.

[41]  S. Jimenez,et al.  Formation of nodular structures resembling mature articular cartilage in long-term primary cultures of human fetal epiphyseal chondrocytes on a hydrogel substrate. , 1994, Arthritis and rheumatism.

[42]  G. Panayi,et al.  Cytokine expression in synovial membranes of patients with rheumatoid arthritis and osteoarthritis. , 1993, Annals of the rheumatic diseases.

[43]  R. Oberbauer,et al.  Pharmacokinetics of Indomethacin in the Elderly , 1993, Clinical pharmacokinetics.

[44]  A. Pitsillides,et al.  Light microscopic characterization of the fibroblast-like synovial intimal cell (synoviocyte). , 1992, Arthritis and rheumatism.

[45]  P. A. Todd,et al.  Diclofenac Sodium , 1988, Drugs.

[46]  G. Herrero-Beaumont,et al.  Prostaglandin E2 receptors EP1 and EP4 are up-regulated in rabbit chondrocytes by IL-1beta, but not by TNFalpha. , 2007, Rheumatology international.

[47]  V. Trevisani,et al.  Diacerein for osteoarthritis. , 2006, The Cochrane database of systematic reviews.

[48]  T. Yoshino,et al.  Prostaglandin E(2) inhibits IL-18-induced ICAM-1 and B7.2 expression through EP2/EP4 receptors in human peripheral blood mononuclear cells. , 2002, Journal of immunology.

[49]  P. Tak,et al.  NF-kappaB: a key role in inflammatory diseases. , 2001, The Journal of clinical investigation.

[50]  P. Tak,et al.  NF-κB: a key role in inflammatory diseases , 2001 .

[51]  F. Berenbaum,et al.  Synergistic effect of interleukin-1 beta and tumor necrosis factor alpha on PGE2 production by articular chondrocytes does not involve PLA2 stimulation. , 1996, Experimental Cell Research.

[52]  M. Nakamura,et al.  Inhibition by angiotensin converting enzyme inhibitors of endothelin secretion from cultured human endothelial cells. , 1992, Life sciences.